{"id":"oxycodone-deterx","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL656","moleculeType":"Small molecule","molecularWeight":"315.37"},"_fixedAt":"2026-03-30T18:37:57.796433","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone DETERx combines the opioid analgesic oxycodone with Collegium's proprietary DETERx technology, which is intended to make the drug resistant to common methods of abuse such as crushing, chewing, or dissolving. The formulation maintains the pharmacological action of oxycodone—binding to mu-opioid receptors in the central nervous system to produce analgesia—while the abuse-deterrent coating aims to reduce diversion and misuse potential.","oneSentence":"Oxycodone DETERx is an extended-release formulation of oxycodone, a mu-opioid receptor agonist, designed with abuse-deterrent technology to reduce the potential for misuse.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:07.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain requiring long-term opioid therapy"}]},"_fixedFields":["pubmed(15)"],"trialDetails":[{"nctId":"NCT01685684","phase":"PHASE3","title":"Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)","status":"COMPLETED","sponsor":"Collegium Pharmaceutical, Inc.","startDate":"2012-08","conditions":"Chronic Low Back Pain","enrollment":740}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"recentPublications":[{"date":"2020 Mar/Apr","pmid":"32329888","title":"Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza(®) ER (oxycodone DETERx(®) formulation): A review of published studies.","journal":"Journal of opioid management"},{"date":"2018 Sep/Oct","pmid":"30387859","title":"Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).","journal":"Journal of opioid management"},{"date":"2018","pmid":"30288095","title":"Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone.","journal":"Journal of pain research"},{"date":"2017 Dec","pmid":"28940174","title":"In Vitro Drug Release After Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations.","journal":"Clinical drug investigation"},{"date":"2017 Aug","pmid":"28600725","title":"Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.","journal":"Drugs & aging"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone DETERx","genericName":"Oxycodone DETERx","companyName":"Collegium Pharmaceutical, Inc.","companyId":"collegium-pharmaceutical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone DETERx is an extended-release formulation of oxycodone, a mu-opioid receptor agonist, designed with abuse-deterrent technology to reduce the potential for misuse. Used for Moderate to severe chronic pain requiring long-term opioid therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}